PolyPid Ltd. (PYPD) Stock Analysis

Why this analysis is different

• A 9-signal quantitative MoonshotScore built from filings, insider activity, and market data — computed from the numbers, not from opinion.
• An AI Council read across up to eight perspectives — value, macro, quantitative, and momentum lenses — that shows where they disagree instead of averaging the tension away.
• Figures come straight from FMP and Yahoo Finance filings data. The AI writes the narrative around the numbers — it never edits the numbers.

PolyPid Ltd. (PYPD) Healthcare & Pipeline Overview

PolyPid Ltd. is a biopharmaceutical company specializing in the development of localized drug delivery solutions using its PLEX technology. Its lead candidate, D-PLEX100, targets surgical site infections, positioning the company within the infection prevention market. The company is based in Israel and has a market cap of $95.6M.

What Is the Investment Thesis for PYPD?

PolyPid Ltd. presents a focused investment opportunity within the biotechnology sector, primarily driven by the potential success of its lead product candidate, D-PLEX100. Currently in Phase III clinical trials, positive results and subsequent regulatory approval for D-PLEX100 in preventing surgical site infections (SSIs) could significantly drive revenue growth. The company's proprietary PLEX technology offers a unique drug delivery platform that could be expanded to other therapeutic areas. However, the company's future hinges heavily on the successful commercialization of D-PLEX100, with potential risks including clinical trial setbacks, regulatory hurdles, and competition from existing SSI prevention methods. With a market cap of $95.6M and a beta of 1.46, PolyPid represents a high-risk, high-reward investment profile.

Based on FMP financials and quantitative analysis

PYPD Key Highlights

D-PLEX100 is in Phase III clinical trials targeting sternal and abdominal surgical site infections (SSIs).

• The company's PLEX technology allows for localized and controlled drug release.
• PolyPid Ltd. is headquartered in Petah Tikva, Israel.
• The company has 57 employees.
• PolyPid Ltd. has a market capitalization of $95.6M.

Who Are PYPD's Competitors?

PYPD is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.

AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance

What Are PYPD's Key Strengths?

Proprietary PLEX technology platform.

• Lead product candidate in Phase III clinical trials.
• Experienced management team.
• Focus on unmet medical needs.

What Are PYPD's Weaknesses?

Reliance on a single lead product candidate.

• Limited financial resources.
• Small number of employees.
• Lack of commercial infrastructure.

What Could Drive PYPD Stock Higher?

Completion of Phase III clinical trials for D-PLEX100 in sternal SSI prevention.

• Announcement of topline results from Phase III clinical trials for D-PLEX100.
• Potential regulatory submission for D-PLEX100 to the FDA and other regulatory agencies.
• Continued development of new PLEX-based products for other therapeutic areas.

What Are the Key Risks for PYPD?

Financial-distress signal — its Altman Z-Score of -30.16 sits in the distress zone (elevated bankruptcy risk).

• Weak fundamentals — a Piotroski F-Score of 1/9 flags soft profitability, leverage or efficiency.
• Clinical trial setbacks or negative results for D-PLEX100.
• Regulatory delays or rejection of D-PLEX100.
• Competition from existing SSI prevention methods.
• Dependence on the success of D-PLEX100.
• Limited financial resources to support ongoing operations and clinical development.

What Are the Growth Opportunities for PYPD?

• Expansion of D-PLEX100 indications: PolyPid has the opportunity to expand the use of D-PLEX100 beyond sternal and abdominal SSIs to other surgical procedures where infection prevention is critical. This could significantly increase the addressable market for D-PLEX100.
• Development of new PLEX-based products: PolyPid's PLEX technology can be applied to develop new products for various therapeutic areas beyond infection prevention. This includes applications in pain management, wound healing, and oncology. Developing new PLEX-based products could diversify the company's revenue streams and reduce reliance on D-PLEX100.
• Strategic partnerships and collaborations: PolyPid can pursue strategic partnerships with larger pharmaceutical companies to co-develop and commercialize its products. This could provide access to additional funding, expertise, and distribution channels. Collaborations can accelerate the development and commercialization of PolyPid's pipeline.
• Geographic expansion: PolyPid can expand its geographic presence by seeking regulatory approvals and commercializing its products in new markets, such as Europe and Asia. This would increase the company's revenue potential and reduce its reliance on the US market. International expansion requires navigating different regulatory landscapes and establishing local partnerships.
• Outlicensing or sale of PLEX technology: PolyPid could outlicense its PLEX technology to other companies for use in their own product development programs. This would generate upfront and royalty payments for PolyPid, providing a non-dilutive source of funding. The value of the PLEX technology lies in its ability to provide controlled and localized drug delivery.

What Are PYPD's Competitive Advantages?

• Proprietary PLEX technology platform for localized drug delivery.
• Patent protection for its products and technology.
• Clinical data supporting the safety and efficacy of its products.
• Expertise in polymer chemistry and drug formulation.

What Does PYPD Do?

PolyPid Ltd., founded in 2008 and headquartered in Petah Tikva, Israel, is a late-stage biopharmaceutical company dedicated to developing, manufacturing, and commercializing innovative pharmaceutical products based on its proprietary Polymer-Lipid Encapsulation Matrix (PLEX) technology. The PLEX platform is designed for the localized, controlled release of drugs directly at the site of disease or injury, aiming to improve therapeutic outcomes and reduce systemic side effects. The company's primary focus is on addressing unmet medical needs in the surgical field, particularly in the prevention of surgical site infections (SSIs). Their lead product candidate, D-PLEX100, is currently in Phase III clinical trials for the prevention of sternal (bone) and abdominal (soft tissue) SSIs. D-PLEX100 is designed to provide a sustained release of antibiotics directly at the surgical site, aiming to reduce the incidence of post-operative infections. PolyPid's strategy involves developing and commercializing its PLEX-based products through strategic partnerships and, potentially, direct sales in select markets. The company operates with 57 employees, focusing on research, development, and clinical trials to bring its innovative products to market.

What Products and Services Does PYPD Offer?

• Develops pharmaceutical products based on the PLEX technology.
• Focuses on localized drug delivery for improved therapeutic outcomes.
• Targets unmet medical needs in the surgical field.
• Conducts clinical trials to evaluate the safety and efficacy of its products.
• Seeks regulatory approvals for its products.
• Commercializes its products through strategic partnerships and direct sales.

How Does PYPD Make Money?

• Develops and patents pharmaceutical products based on its PLEX technology.
• Conducts clinical trials to demonstrate the safety and efficacy of its products.
• Seeks regulatory approvals from agencies like the FDA.
• Commercializes approved products through strategic partnerships and direct sales.

What Industry Does PYPD Operate In?

PolyPid Ltd. operates within the biotechnology industry, specifically focusing on localized drug delivery systems. The market for surgical site infection (SSI) prevention is substantial, driven by the increasing number of surgical procedures performed globally and the rising costs associated with treating SSIs. The competitive landscape includes established pharmaceutical companies offering systemic antibiotics and other infection control measures. PolyPid's PLEX technology offers a differentiated approach by providing localized and sustained drug release, potentially reducing the risk of systemic side effects and improving efficacy. The biotechnology industry is characterized by high R&D costs, long development timelines, and regulatory hurdles, but successful products can achieve significant market penetration and profitability.

Who Are PYPD's Key Customers?

• Hospitals and surgical centers.
• Surgeons and other healthcare professionals.
• Patients undergoing surgical procedures.

Wall Street analysts project PolyPid Ltd. revenue of about $850K for fiscal 2026, with EPS near $-1.73. The estimate reflects 3 contributing analysts.

PYPD Valuation & Market Position

With a $95.6M market cap, PolyPid Ltd. sits in the micro-cap segment of the market. Relative to its peer group, PYPD's quantitative score of 52/100 is below the peer average of 73/100.

Key Financial Metrics

Its free cash flow yield is 0.0%, a gauge of the cash the business throws off relative to its market value. A current ratio of 1.78 indicates the company holds enough short-term assets to cover its near-term obligations. Its earnings yield is -31.7%, the inverse of the P/E and a quick read on earnings relative to price.

PolyPid Ltd.'s Piotroski F-Score is 1/9, a 9-point checklist of profitability, leverage and efficiency — flagging fundamental weakness worth scrutiny. Its Altman Z-Score of -30.16 places it in the distress zone, a signal of elevated financial risk.

PolyPid Ltd. has beaten Wall Street's EPS estimate in 4 of its last 8 reported quarters — more hits than misses. Reported results have landed about 3.8% below estimates on average.

Company Profile

PolyPid Ltd. operates in the Biotechnology industry within the Healthcare sector. It is headquartered in Petah Tikva, IL. The company is led by CEO Dikla Czaczkes Akselbrad. PYPD has traded publicly since 2020.

PYPD Financials

PYPD Latest News

PYPD Analyst Consensus

PYPD MoonshotScore

PolyPid Ltd. Healthcare Stock: Key Questions Answered

Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.

Official Resources